Actions

CD38: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
Line 77: Line 77:
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
|-
|-
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|-
|-
|}
|}

Revision as of 10:52, 8 May 2023


Summary
CD38 helps mobilise intracellular calcium to activate a wide array of cell functions. In haematological cell types CD38 it is widely expressed by lymphoid cells B, T and NK) as well as myeloid precursor cells and mature myeloid cells.
CD38 has particular diagnostic importance for lymphocytes where CD38 expression is acquired as stem cells commit to B-cell lineage, then is lost as mature B cells emerge from bone marrow before being re-acquired at the time of plasma cell differentiation.




Normal expression and function

The wide expression of CD38 limits its diagnostic value except in very specific circumstances:

  • The co-expression of CD38 with CD138 can identify normal or neoplastic plasma cells
  • Expression of CD38 in chronic lymphocytic leukaemia (>20% of cells) may associated with poorer outcome


Other relevant information:

CD38 is a therapeutic target, daratumumab is a monoclonal antibody which binds to CD38 and is used in the treatment of myeloma.




Expression in primitive cell types
AML CMML B ALL Burkitt T ALL ETP ALL <I> MPAL <I> Hgns <I>
2-20%* 40-80% 40-80% 40-80% 40-80% 40-80% 40-80% 80-100%*

Notes: * expression correlates with subtype, particularly APML. Expression by haematogones is very high.


Expression in mature B cell neoplasms
CLL MCL FL MZL HCL DLBCL LPL PCL
2-20%* 80-100% 80-100% 80-100% 2-20% 80-100%* 40-80% 80-100%**

Notes: Expression level in CLL and DLBCL may have prognostic value, plasma cells express the marker fairly consistently although the levels can vary.


Expression in mature T cell neoplasms
ATLL CTCL/Sezary T-PLL T-LGL NK-LGL
80-100% 80-100% 80-100% 80-100% 80-100%